[go: up one dir, main page]

FR2974370B1 - Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad - Google Patents

Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad

Info

Publication number
FR2974370B1
FR2974370B1 FR1153533A FR1153533A FR2974370B1 FR 2974370 B1 FR2974370 B1 FR 2974370B1 FR 1153533 A FR1153533 A FR 1153533A FR 1153533 A FR1153533 A FR 1153533A FR 2974370 B1 FR2974370 B1 FR 2974370B1
Authority
FR
France
Prior art keywords
tgf
pigment
smad signaling
beta
relates
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
FR1153533A
Other languages
English (en)
Other versions
FR2974370A1 (fr
Inventor
Francoise Bernerd
Christine Duval
Lacharriere Olivier De
Stephanie Nouveau
Xavier Marat
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LOreal SA
Original Assignee
LOreal SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR1153533A priority Critical patent/FR2974370B1/fr
Application filed by LOreal SA filed Critical LOreal SA
Priority to CN201280030372.8A priority patent/CN103619318B/zh
Priority to EP12722443.4A priority patent/EP2699221B1/fr
Priority to ES12722443.4T priority patent/ES2624671T3/es
Priority to PCT/FR2012/050860 priority patent/WO2012172220A1/fr
Priority to JP2014505704A priority patent/JP6181042B2/ja
Priority to KR1020137031099A priority patent/KR102072783B1/ko
Priority to US14/111,802 priority patent/US20150307940A1/en
Publication of FR2974370A1 publication Critical patent/FR2974370A1/fr
Application granted granted Critical
Publication of FR2974370B1 publication Critical patent/FR2974370B1/fr
Priority to JP2017079650A priority patent/JP6836950B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7105—Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7004—Monosaccharides having only carbon, hydrogen and oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
    • A61K8/35—Ketones, e.g. benzophenone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4926—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having six membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/60—Sugars; Derivatives thereof
    • A61K8/606—Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/04—Preparations for care of the skin for chemically tanning the skin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Birds (AREA)
  • Molecular Biology (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Botany (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une signature moléculaire des taches pigmentaires cutanées, comprenant les gènes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 et SOSTDC1, et diverses applications de cette signature. L'invention concerne notamment une méthode de caractérisation d'une tache pigmentaire apparente ou soupçonnée chez un être humain, comprenant la comparaison des niveaux d'expression, dans des échantillons de peau issue de ladite tache et de peau adjacente non lésée, d'au moins un gène dermique lié à la voie de signalisation TGF-β - SMAD choisi parmi la liste constituée des gènes TGFBR2, TGFBI, BMP2, SMAD3, THBS2, TGFBR3, SEMA5A, SMAD7 et SOSTDC1. L'invention concerne également des méthodes d'évaluation de l'efficacité d'un traitement des taches pigmentaires, des méthodes cosmétiques et thérapeutiques de traitement des taches pigmentaires, ainsi que divers modulateurs desdits gènes et leur utilisation.
FR1153533A 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad Expired - Fee Related FR2974370B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR1153533A FR2974370B1 (fr) 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad
EP12722443.4A EP2699221B1 (fr) 2011-04-22 2012-04-20 Signature moléculaire des taches pigmentaires cutanées, associée à la matrice extracellulaire
ES12722443.4T ES2624671T3 (es) 2011-04-22 2012-04-20 Firma molecular de manchas pigmentarias cutáneas, asociada a la matriz extracelular
PCT/FR2012/050860 WO2012172220A1 (fr) 2011-04-22 2012-04-20 Signature moléculaire des taches pigmentaires cutanées, associée à la matrice extracellulaire
CN201280030372.8A CN103619318B (zh) 2011-04-22 2012-04-20 和细胞外基质相关的皮肤色斑分子标签
JP2014505704A JP6181042B2 (ja) 2011-04-22 2012-04-20 細胞外マトリックスに関連した皮膚色素斑の分子シグネチャー
KR1020137031099A KR102072783B1 (ko) 2011-04-22 2012-04-20 세포외 매트릭스와 연관되는, 피부 색소 반점의 분자 지표
US14/111,802 US20150307940A1 (en) 2011-04-22 2012-04-20 Molecular signature of cutaneous pigmentary spots, associated with the extracellular matrix
JP2017079650A JP6836950B2 (ja) 2011-04-22 2017-04-13 細胞外マトリックスに関連した皮膚色素斑の分子シグネチャー

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR1153533A FR2974370B1 (fr) 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad

Publications (2)

Publication Number Publication Date
FR2974370A1 FR2974370A1 (fr) 2012-10-26
FR2974370B1 true FR2974370B1 (fr) 2016-09-02

Family

ID=44645730

Family Applications (1)

Application Number Title Priority Date Filing Date
FR1153533A Expired - Fee Related FR2974370B1 (fr) 2011-04-22 2011-04-22 Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad

Country Status (1)

Country Link
FR (1) FR2974370B1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4226911A1 (fr) * 2022-02-09 2023-08-16 CUTANEON - Skin & Hair Innovations GmbH Agent actif modulant l'activité d'un canal ionique utilisé pour la régulation de la pigmentation de la peau
FR3135992A1 (fr) 2022-05-25 2023-12-01 L'oreal Signature moléculaire du lentigo actinique associée à la gestion des vésicules

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7622117B2 (en) * 2002-04-17 2009-11-24 Dynamis Therapeutics, Inc. 3-deoxyglucosone and skin
EP2626437A3 (fr) * 2008-05-14 2013-12-11 Dermtech International Diagnostic de mélanome et de lentigo solaire par l'analyse d'acides nucléiques
FR2953220B1 (fr) * 2009-12-01 2012-11-23 Oreal Signature microarn de la differenciation epidermique et utilisations

Also Published As

Publication number Publication date
FR2974370A1 (fr) 2012-10-26

Similar Documents

Publication Publication Date Title
EA200901166A1 (ru) Соединения и композиции в качестве модуляторов активности gpr 119
DK1766077T3 (da) Differentielt udtrykte gener og veje i bipolar forstyrrelse og/eller alvorlig depressiv forstyrrelse
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
WO2018112446A3 (fr) Utilisation de gènes à médiation par motif apoe4 pour le diagnostic et le traitement de la maladie d'alzheimer
EA200701036A1 (ru) Лактамные соединения и их применение в качестве фармацевтических препаратов
DE502005010615D1 (de) Mittel zur behandlung von entzündlichen erkrankungen
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
BR112013008140A8 (pt) "compostos imidazotriazinona".
EA200870594A1 (ru) Связывающие человеческие молекулы с киллерной активностью в отношении энтерококков и их применение
MX340231B (es) Enzimas fluidas incubadas y usos de las mismas.
EA200901067A1 (ru) Использование семафорина 6а в качестве промотора миелинизации и дифференцировки олигодендроцитов
WO2007103373A3 (fr) Compositions et procédés pour le traitement de troubles immunoinflammatoires
BR112014017751A8 (pt) compostos inibidores de metaloenzima, métodos de inibir e modular a atividade de metaloenzina, composições contendo os ditos compostos e uso dos ditos compostos
WO2010011283A3 (fr) Composés à base de fus/tls et méthodes de diagnostic, traitement et prévention d'une sclérose latérale amyotrophique et de maladies des motoneurones apparentées
ATE472998T1 (de) Kationische liposomale zubereitungen zur behandlung von rheumatoider arthritis
BR112016028446A2 (pt) inibidor de complemento de ornithodoros moubata para uso no tratamento de doenças mediadas por complemento em pacientes com polimorfismo de c5
MX2018014047A (es) Firmas de genes estromales para el diagnóstico y uso en inmunoterapia.
MA38190A2 (fr) Inhibiteurs d'autotaxine
MA34291B1 (fr) Compositions et méthodes de diagnostic et de traitement d'une tumeur
WO2012172221A3 (fr) Signature moléculaire des taches pigmentaires cutanées, associée à l'organisation de la matrice extracellulaire
FR2974370B1 (fr) Signature moleculaire des taches pigmentaires cutanees, associee a la voie de signalisation tgf-beta - smad
WO2018049003A8 (fr) Composés inhibiteurs de sialidase anti-fibrotique et leurs méthodes d'utilisation
EP2588630A4 (fr) Approche génétique moléculaire pour traitement et diagnostic de dépendance à l'alcool et aux médicaments
Abdullah et al. Diverse effects of lead nitrate on the proliferation, differentiation, and gene expression of stem cells isolated from a dental origin

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 6

PLFP Fee payment

Year of fee payment: 7

PLFP Fee payment

Year of fee payment: 8

PLFP Fee payment

Year of fee payment: 9

PLFP Fee payment

Year of fee payment: 10

ST Notification of lapse

Effective date: 20211205